Milestone: 10,000 Diagnostic & 100,000 Genomic NGS Samples

March 06, 2013

FOR IMMEDIATE RELEASE

Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656

Ambry Genetics Achieves Company Milestone, Surpasses 10,000 Diagnostic and 100,000 Genomics Next Generation Sequencing Samples

NGS technologies provide direct clinical benefit to patient care and expand genomics research.

Aliso Viejo, CA – March 6, 2013 - Ambry Genetics, a global leader in clinical diagnostics and genomic services, announced today that they have officially reached a new milestone in Next-Gen sequencing.

“We have reached an incredible milestone in next-generation sequencing (NGS)," said Ardy Arianpour, Vice President of Business Development at Ambry Genetics." Ever since NGS was launched, we have worked diligently to build a customer-centric business to provide our clients with the tools and resources they need to successfully reach their goals. Our clients have shown us loyalty that is reflected in the numbers.”

Ambry invested in NGS in 2007 when it was first commercially available and soon after launched their genomic services division running large academic, biotech and government projects. Building on years of experience, Ambry was first to offer an NGS based diagnostic test in April 2010, with the introduction of an 81-gene panel for X-Linked intellectual disability. NGS is ideal for analyzing large sets of genes involved in molecularly heterogeneous disorders, reducing both cost and turn-around-time over traditional Sanger sequencing.

These aspects are crucial where test results can have a direct affect on medical management or family planning. With that in mind, in 2011 Ambry launched the Clinical Diagnostic Exome^TM, making them the first CLIA-certified laboratory to offer whole-exome sequencing clinically. These successes were followed by Marfan syndrome and the Primary Cilia­ry Dyskinesia NGS panels. Last year, Ambry continued its release of innovative NGS panels with its widely adopted hereditary cancer syndrome product line and most recently its hereditary cardiovascular disease panels.

Ambry remains at the forefront of technology and diagnostics. Incorporating feedback from clients, scientists and market research analysis, Ambry continues to develop and enhance their comprehensive testing menu. Significant laboratory automation investments, enhancements and restructuring has allowed Ambry to focus on reducing test turn-around-time (TAT). Accordingly, Ambry has reduced its full CFTR sequencing plus deletion and duplication analysis TAT in half to five-to-thirteen days. This is the fastest turn-around-time in the world for CFTR sequencing and marks only the beginning of improvements to come.

"As a company, Ambry Genetics is fully committed to providing answers through cutting-edge science and operational improvements, said Charles Dunlop, Chief Executive Officer at Ambry Genetics. Watching the company grow has been sensational, but something tells me the coming years will be the best to come."